Net Worth Advisory Group Makes New $437,000 Investment in Edwards Lifesciences Co. (NYSE:EW)

Net Worth Advisory Group acquired a new stake in Edwards Lifesciences Co. (NYSE:EW) in the 3rd quarter, according to the company in its most recent filing with the SEC. The fund acquired 6,616 shares of the medical research company’s stock, valued at approximately $437,000.

A number of other institutional investors also recently modified their holdings of the stock. Aaron Wealth Advisors LLC bought a new stake in Edwards Lifesciences in the third quarter valued at $273,000. V Square Quantitative Management LLC lifted its holdings in Edwards Lifesciences by 10.6% during the third quarter. V Square Quantitative Management LLC now owns 15,026 shares of the medical research company’s stock worth $992,000 after acquiring an additional 1,437 shares during the period. Trust Co. of Vermont boosted its position in Edwards Lifesciences by 36.1% in the third quarter. Trust Co. of Vermont now owns 3,019 shares of the medical research company’s stock worth $199,000 after purchasing an additional 801 shares during the last quarter. nVerses Capital LLC bought a new position in Edwards Lifesciences in the 3rd quarter valued at $792,000. Finally, Vontobel Holding Ltd. increased its position in shares of Edwards Lifesciences by 5.7% during the 3rd quarter. Vontobel Holding Ltd. now owns 439,106 shares of the medical research company’s stock valued at $28,977,000 after purchasing an additional 23,560 shares during the last quarter. Institutional investors and hedge funds own 79.46% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently weighed in on EW shares. Wolfe Research upgraded shares of Edwards Lifesciences from an “underperform” rating to a “peer perform” rating in a research report on Monday, July 29th. Bank of America lowered shares of Edwards Lifesciences from a “buy” rating to a “neutral” rating and reduced their price objective for the company from $105.00 to $75.00 in a research note on Thursday, July 25th. Citigroup reduced their target price on Edwards Lifesciences from $83.00 to $77.00 and set a “buy” rating for the company in a research report on Tuesday, October 1st. StockNews.com cut Edwards Lifesciences from a “buy” rating to a “hold” rating in a report on Thursday, July 25th. Finally, Royal Bank of Canada cut their price objective on Edwards Lifesciences from $85.00 to $75.00 and set an “outperform” rating for the company in a report on Tuesday, October 8th. Fifteen investment analysts have rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $75.81.

Edwards Lifesciences Price Performance

NYSE:EW opened at $70.27 on Friday. The business’s 50-day simple moving average is $67.81 and its two-hundred day simple moving average is $79.18. Edwards Lifesciences Co. has a 52 week low of $58.93 and a 52 week high of $96.12. The stock has a market cap of $42.34 billion, a PE ratio of 30.29, a P/E/G ratio of 2.83 and a beta of 1.13. The company has a quick ratio of 2.87, a current ratio of 3.71 and a debt-to-equity ratio of 0.08.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Wednesday, July 24th. The medical research company reported $0.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.69 by $0.01. Edwards Lifesciences had a return on equity of 22.35% and a net margin of 24.55%. The company had revenue of $1.63 billion for the quarter, compared to the consensus estimate of $1.65 billion. During the same quarter last year, the company earned $0.66 EPS. The firm’s quarterly revenue was up 6.7% on a year-over-year basis. As a group, analysts forecast that Edwards Lifesciences Co. will post 2.71 EPS for the current fiscal year.

Insider Activity at Edwards Lifesciences

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 5,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 14th. The stock was sold at an average price of $66.08, for a total transaction of $330,400.00. Following the completion of the transaction, the vice president now owns 46,936 shares in the company, valued at $3,101,530.88. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In related news, VP Donald E. Bobo, Jr. sold 5,000 shares of Edwards Lifesciences stock in a transaction that occurred on Wednesday, August 14th. The shares were sold at an average price of $66.08, for a total transaction of $330,400.00. Following the transaction, the vice president now directly owns 46,936 shares of the company’s stock, valued at $3,101,530.88. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, VP Daveen Chopra sold 1,250 shares of the firm’s stock in a transaction dated Tuesday, August 20th. The shares were sold at an average price of $69.95, for a total transaction of $87,437.50. Following the completion of the sale, the vice president now owns 29,333 shares in the company, valued at $2,051,843.35. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 16,250 shares of company stock worth $1,099,238. Insiders own 1.29% of the company’s stock.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.